UK2.F Shandong Weigao Group Medical Polymer Company Limited
- Market cap
- EUR 1.58B
- P/E
- 8.8x
- P/B
- 0.49x
- ROE
- 6.7%
- Dividend yield
- 5.32%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is UK2.F undervalued?
Graham numberUK2.F trades 56.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Weigao Group Medical Polymer Company Limited fundamental analysis
No fundamental analysis for Shandong Weigao Group Medical Polymer Company Limited yet.
Shandong Weigao Group Medical Polymer Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Weigao Group Medical Polymer Company Limited
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People's Republic of China and internationally. It operates through Medical Device Products, Orthopedic Products, Pharma Packaging Products, Interventional Products, Blood Management Products, and Others segments. The company offers medical device products, including safe infusion, clinical nursing, perioperative, endocrine,…
Full company profileShandong Weigao Group Medical Polymer Company Limited financial statements
Shandong Weigao Group Medical Polymer Company Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.73B | 6.29B | 8.81B | 10.4B | 11.3B | 13.2B | 13.6B | 13.2B | 13.1B | 13.4B |
| Gross Profit | 4.14B | 3.99B | 5.39B | 6.51B | 6.46B | 7.27B | 7.11B | 6.64B | 6.58B | 6.37B |
| Operating Income | 1.23B | 1.36B | 1.70B | 2.35B | 2.49B | 3.12B | 3.15B | 2.30B | 2.39B | 1.93B |
| EBITDA | - | 1.92B | 2.62B | 3.26B | 2.67B | 2.98B | 4.31B | 3.55B | 3.78B | 3.27B |
| Net Income | 1.11B | 1.73B | 1.47B | 1.84B | 2.03B | 2.24B | 2.72B | 2.00B | 2.07B | 1.61B |
| EPS | - | 0.38 | 0.33 | 0.41 | 0.45 | 0.50 | 0.60 | 0.44 | 0.46 | 0.36 |
| Balance Sheet | ||||||||||
| Total Assets | 15.8B | 16.8B | 24.0B | 26.3B | 27.3B | 30.4B | 33.2B | 33.7B | 34.8B | 36.0B |
| Total Liabilities | 3.55B | 3.14B | 8.80B | 9.33B | 8.95B | 9.46B | 9.75B | 9.68B | 9.42B | 10.2B |
| Shareholders' Equity | 11.9B | 13.3B | 14.5B | 16.2B | 17.5B | 19.3B | 21.7B | 22.4B | 23.8B | 24.1B |
| Cash & Short-term Investments | 4.07B | 3.78B | 3.81B | 4.24B | 5.51B | 6.63B | 6.86B | 6.99B | 7.78B | 8.57B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.05B | 1.27B | 2.22B | 2.32B | 2.79B | 3.04B | 2.21B | 2.80B | 2.79B | 2.55B |
| Capital Expenditure | 639M | 1.43B | 795M | 942M | 908M | 1.07B | 1.12B | 686M | 647M | 833M |
| Free Cash Flow | - | -246M | 1.42B | 1.34B | 1.70B | 1.92B | 1.10B | 2.11B | 2.14B | 1.72B |
| Ratios | ||||||||||
| ROE | 9.3% | 13.0% | 10.1% | 11.4% | 11.6% | 11.7% | 12.6% | 8.9% | 8.7% | 6.7% |
| ROA | 7.0% | 10.3% | 6.1% | 7.0% | 7.4% | 7.4% | 8.2% | 5.9% | 5.9% | 4.5% |
| Net Profit Margin | 16.4% | 27.5% | 16.7% | 17.8% | 17.9% | 17.1% | 20.0% | 15.1% | 15.8% | 12.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shandong Weigao Group Medical Polymer Company Limited dividends
- Dividend yield
- 5.32%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 64.0%
- Ex-dividend date
- Oct 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.03B | 0.23 | 64.0% |
| 2024 | CNY 871M | 0.19 | 42.1% |
| 2023 | CNY 733M | 0.16 | 36.6% |
| 2022 | CNY 742M | 0.16 | 27.2% |
| 2021 | CNY 653M | 0.14 | 29.1% |
| 2020 | CNY 701M | 0.16 | 34.5% |
| 2019 | EUR 711M | 0.16 | 38.6% |
| 2018 | EUR 218M | 0.05 | 14.8% |
| 2017 | EUR 491M | 0.11 | 28.4% |
| 2016 | EUR 253M | - | 22.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on May 4, 2011.
Who owns Shandong Weigao Group Medical Polymer Company Limited
- Insiders 47.75%
- Institutions 21.26%
- Public & others 30.99%
- Shares outstanding 4.44B
- Free float 2.36B
Shandong Weigao Group Medical Polymer Company Limited company profile
- Company name
- Shandong Weigao Group Medical Polymer Company Limited
- Ticker
- UK2.F
- ISIN
- CNE100000171
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 13,310
- Fiscal year end
- December
- Address
- 1 Weigao Road, Weihai, China, 264210
- Phone
- 86 400 646 6666
- Website
- weigaogroup.com
About Shandong Weigao Group Medical Polymer Company Limited
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People's Republic of China and internationally. It operates through Medical Device Products, Orthopedic Products, Pharma Packaging Products, Interventional Products, Blood Management Products, and Others segments. The company offers medical device products, including safe infusion, clinical nursing, perioperative, endocrine, urinary, rehabilitation system, and extracorporeal circulation solutions; pharma packaging products comprising prefilled drug delivery system, pharmaceutical packaging consumables, and automatic drug delivery systems; and orthopedic products that include spine, joint, trauma, sports medicine, bone repair material, and spinal endoscope products, as well as orthopedic devices, PRP treatment consumables, and negative pressure drainage consumables. It also provides interventional products, such as tumor, vascular, and nursing interventions, as well as blood management products, including whole blood collection consumables and blood transfusion equipment. In addition, the company manufactures and sells medical PVC granules, plastic packing bags, and carton boxes; manufacture and sale of medical polymer materials and products; injection puncture instruments; computer technical services; and X-ray based irradiation machines. Further, it provides finance leasing, factoring, and consulting services. The company was founded in 1988 and is based in Weihai, the People's Republic of China.
Shandong Weigao Group Medical Polymer Company Limited management
6- Mr. Jing LongExecutive Chairman of the Board & Compliance Officer · born 1975
- Mr. Rinan CongCEO & Executive Director · born 1981
- Mr. Junqiang LuExecutive Director · born 1974
- Mr. Daoming WangExecutive Director · born 1979
- Mr. Xue Feng WuChief Financial Officer · born 1978
- Ms. Miu Ling Wong ACIS, FCIS, FCSCompany Secretary · born 1969